Atlas Trials

A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease

Clinical trial NCT03478956 · TERMINATED

Trial details

NCT number
NCT03478956
Sponsor
Hoffmann-La Roche
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Ulcerative ColitisCrohn's Disease
Start date
2018-03-27
Primary completion
2019-12-02
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.